A Phase I/II, Open-Label, Non-Randomized, Multicenter, Single Agent Study Of Intravenous SDX-102 For The Treatment Of Patients With MTAP-Deficient High Grade Recurrent Malignant Gliomas
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2016
At a glance
- Drugs SDX 102 (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 25 Oct 2007 Status changed from suspended to completed.
- 22 Aug 2005 New trial record.